Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-05-22
DOI
10.3389/fimmu.2019.00999
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
- (2018) Robert L. Ferris et al. CANCER TREATMENT REVIEWS
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
- (2018) Silvia C. Formenti et al. CLINICAL CANCER RESEARCH
- Bifacial effects of engineering tumour cell-derived exosomes on human natural killer cells
- (2018) Qi Li et al. EXPERIMENTAL CELL RESEARCH
- The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
- (2018) Xiaoling Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
- (2018) Junko Tanizaki et al. Journal of Thoracic Oncology
- Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma
- (2018) Kendra C. Foley et al. MELANOMA RESEARCH
- mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma
- (2018) Yuhua Wang et al. MOLECULAR THERAPY
- Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT
- (2018) Elizabeth K. Duperret et al. MOLECULAR THERAPY
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
- (2018) Rindert Missiaen et al. SEMINARS IN CANCER BIOLOGY
- The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
- (2018) Yayi He et al. Drug Design Development and Therapy
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Immuno-Oncology: Emerging Targets and Combination Therapies
- (2018) Henry T. Marshall et al. Frontiers in Oncology
- Cemiplimab Approved for Treatment of CSCC
- (2018) Cancer Discovery
- Second- and third-generation drugs for immuno-oncology treatment—The more the better?
- (2017) Wolfram C.M. Dempke et al. EUROPEAN JOURNAL OF CANCER
- Immune recognition of irradiated cancer cells
- (2017) Erik Wennerberg et al. IMMUNOLOGICAL REVIEWS
- Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality
- (2017) Andreas Pircher et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review)
- (2017) Jinjing Xu et al. Molecular Medicine Reports
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
- (2017) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance
- (2017) Bhargavi Pulluri et al. PHARMACOLOGICAL RESEARCH
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
- (2017) Claire Lhuillier et al. SEMINARS IN CANCER BIOLOGY
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
- (2017) Claire Vanpouille-Box et al. Nature Communications
- Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells
- (2017) Nils-Petter Rudqvist et al. Cancer Immunology Research
- PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
- (2017) Gabriele Madonna et al. OncoImmunology
- Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
- (2017) Nathan O. Siemers et al. PLoS One
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
- (2016) Zachary S. Morris et al. CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
- (2016) Laura Q.M. Chow et al. CLINICAL CANCER RESEARCH
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- (2016) Toni K. Choueiri et al. CLINICAL CANCER RESEARCH
- Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
- (2016) KM Morrissey et al. CTS-Clinical and Translational Science
- Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma
- (2016) Tai Hato et al. Immunotherapy
- Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells
- (2016) Koji Nakamura et al. MOLECULAR CANCER RESEARCH
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
- (2016) Danny N. Khalil et al. Nature Reviews Clinical Oncology
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment
- (2016) MINGYUE LI et al. ONCOLOGY REPORTS
- Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells
- (2016) Shu Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer
- (2016) Hong Zheng et al. Oncotarget
- Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy
- (2016) A. M. Trotta et al. Cancer Immunology Research
- Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy
- (2016) D. B. Page et al. Cancer Immunology Research
- Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
- (2016) Seongseok Yun et al. Cancer Medicine
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response inKRASwild-type metastatic colorectal cancer patients
- (2016) Cristiana Lo Nigro World Journal of Gastrointestinal Oncology
- Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine
- (2015) Yasuhiko Ohshio et al. CANCER SCIENCE
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
- (2015) Santiago Zelenay et al. CELL
- Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions
- (2015) A. Filatenkov et al. CLINICAL CANCER RESEARCH
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer
- (2015) Rebecca S. Heist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy
- (2015) Jennifer A. Wargo et al. SEMINARS IN ONCOLOGY
- In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
- (2015) Claire Vanpouille-Box et al. VACCINE
- Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
- (2015) Andreas D. Ørskov et al. Oncotarget
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation-Induced IFN- Production within the Tumor Microenvironment Influences Antitumor Immunity
- (2014) A. A. Lugade et al. JOURNAL OF IMMUNOLOGY
- Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression
- (2014) liufu deng et al. OncoImmunology
- Targeting COX-2 abrogates mammary tumorigenesis
- (2014) Nune Markosyan et al. OncoImmunology
- Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
- (2014) Jing Lu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- (2013) Vikash P. Chauhan et al. Nature Communications
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer
- (2013) E. B. Golden et al. Cancer Immunology Research
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Primary Tumor Hypoxia Recruits CD11b+/Ly6Cmed/Ly6G+Immune Suppressor Cells and Compromises NK Cell Cytotoxicity in the Premetastatic Niche
- (2012) Jaclyn Sceneay et al. CANCER RESEARCH
- Exosome removal as a therapeutic adjuvant in cancer
- (2012) Annette M Marleau et al. Journal of Translational Medicine
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-EGFR Antibody Cetuximab Enhances the Cytolytic Activity of Natural Killer Cells toward Osteosarcoma
- (2011) J. H. W. Pahl et al. CLINICAL CANCER RESEARCH
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Macrophage Expression of Hypoxia-Inducible Factor-1 Suppresses T-Cell Function and Promotes Tumor Progression
- (2010) A. L. Doedens et al. CANCER RESEARCH
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors
- (2010) Barbara Seliger et al. TRENDS IN MOLECULAR MEDICINE
- Systemic effects of local radiotherapy
- (2009) Silvia C Formenti et al. LANCET ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started